Shares of Ocugen Inc. (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, fell 3.7% in Wednesday’s regular trading session.
Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts.
Pfizer Inc (NYSE: PFE) and the Indian government are at loggerheads over a demand by the company for legal protection from any claims linked to the use of its COVID-19 vaccine, said
Along with the approval of Moderna’s COVID-19 vaccine, Japan’s regulatory authority has also approved AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine, Vaxzevria for…